PaxMedica Plans to Initiate Phase 1B Study for PAX-101 in Patients with Long COVID-19 Syndrome Fri January 7, 2022 | 07:25 am Press Release PaxMedica Plans to Initiate Phase 1B Study for PAX-101 in Patients with Long COVID-19 Syndrome January 24, 2022 By Greg Barton 0 comments - Study has been approved by the South African Health Authority for individuals with documented COVID-19 infections who develop...
Timber Pharmaceuticals to Host Conference Call Discussing Positive Topline Results from Phase 2b CONTROL Study of Congenital Ichthyosis for Lead Asset, TMB-001 Wed November 17, 2021 | 08:00 am Press Release Timber Pharmaceuticals to Host Conference Call Discussing Positive Topline Results from Phase 2b CONTROL Study of Congenital Ichthyosis for Lead Asset, TMB-001 January 24, 2022 By Greg Barton 0 comments call to be held on Monday, November 22 nd at 10:00am ET BASKING RIDGE, NJ, Nov. 17, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tim...
Timber Pharmaceuticals Announces Closing of $15 Million Public Offering Fri November 5, 2021 | 08:30 am Press Release Timber Pharmaceuticals Announces Closing of $15 Million Public Offering January 24, 2022 By Greg Barton 0 comments Basking Ridge, NJ, Nov. 05, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NY...